title: Neoadjuvant treatment of early-stage resectable non-small-cell lung cancer.
abstract: New approaches to the treatment of locally advanced non-small-cell lung cancer (NSCLC) include a focus on improving survival for patients with stage-III disease, which has traditionally implied regionally advanced, yet potentially surgically resectable, disease. Neoadjuvant, or induction, therapy has been one such focus in order to improve control of systemic disease. The use of neoadjuvant chemotherapy with surgery appears to increase median survival and, perhaps more importantly, may enhance long-term survival, indicating cure. Clinical trials assessing the feasibility and efficacy of docetaxel, a taxane with considerable activity in NSCLC, alone or in combination with a platinum analog, have yielded promising results. Current research focuses on optimal integration of neoadjuvant chemotherapy into treatment strategies for patients with early-stage and locally advanced NSCLC.
authors.affiliation: Institute of Medical Oncology, University of Bern, 3010 Bern, Switzerland. Daniel.betticher@insel.ch
authors.forename: Daniel C
authors.initials: DC
authors.lastname: Betticher
authors.forename: Rafael
authors.initials: R
authors.lastname: Rosell
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000601:surgery; D002986:Clinical Trials as Topic; D000077143:Docetaxel; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000601:surgery; D020360:Neoadjuvant Therapy / Q000379:methods*; D009367:Neoplasm Staging; D043823:Taxoids / Q000627:therapeutic use*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel